Case report instructions

Once you are finished with the EUSOP program, and before you get the certification, there is one more step to be done. You need to submit a case report. The case report should be in connection with the topics that you have heard in EUSOP program.

1/ How do you choose a case for a case report or clinical case report?
In practice, this case report must be based on a “real-world” professional case where you were involved. This can be,

- in connection with a dysfunction, “poor organisation, non-compliance with standards in your department (technical or human organization) you identified and decided to rectify.
- implementation, or evolution of a new oncology pharmaceutic activity

This (pharmaceutic) case report can be typically in connection with topics from EUSOP chapter 1 and 2 (cytotoxics or Mabs preparation and quality/ security procedures, prescription check, medication use process and risk management, clinical trials, oral therapies…). Reports can be also generated from topics of chapter 3 for clinical pharmacy or chapter 4 (examples of biosimilars implementation) with a lot of possibilities to report cases of implementation of a new activity: pharmaceutical care plan, patient counselling, medication reconciliation.

You can choose to report more specifically a **“clinical case report”** (in connection with topics 3L from chapter 3 “clinical presentations and treatment”). In this case you will have to highlight add-value of clinical oncology pharmacist and show how clinical pharmacist is involved in optimizing medication use, using “tools” of clinical pharmacy.

In any case, the chosen case have to highlight role of oncology pharmacist in improving cancer care.

2/ Redaction of case report

This must be a synthetic report (2 pages) (not more than 1000 words) using word file (for text use Arial 11). You can add annexes (with figures or photo if necessary).

Include:
date, name of author and hospital affiliation
case report's title
drug prescription: **use systematically INN** to facilitate international identification
if chemotherapy regimen, precise the complete regimen (at least once) and patient's Body Surface Area

Pharmaceutic case report:

- Brief presentation of your hospital, pharmacy department and your responsibilities.
- Description of the case

- Analysis of the situation, problem
- Evolution : corrective actions, implementation of a new activity or organisation
- Conclusion with summary points: what lessons can be learned from this case report?

You can add 5 max references if you use some guidelines or articles

Extra paragraph:
Identify EUSOP topics in connection with your case. And briefly, how EUSOP lectures helped or motivated in this case.

Clinical case report
- Patient description (diagnose and cancer history, comorbidities, risk factors)
- Brief case history: the case is best presented in chronological order. Include biology data if in connection with medication (ex renal function)
- Focus will be done on therapeutic aspects and medications including lines of therapy (all unnecessary details have to be excluded!)
- Clinical oncology pharmacy actions: how did you act as clinical oncology pharmacist for this cancer patient (action in tumor board, medication review and pharmaceutic interventions, reconciliation, patient counselling….)
- A short conclusion (5 lines maximum) with a result of pharmacist intervention.

If needed for clarification, you can contact Christophe Bardin:
christophe.bardin@aphp.fr

1. Please send your case report to membershipservice@esop.li.
2. Membership service will send the case report to Mina Kovačevič and Christophe Bardin.
3. Once checked by Education committee, you will get the feedback from Membership service.

The case report should be a presentation of an oncology pharmacy situation or one cancer patient, that you came across and it was interesting for you. Your hands are opened in terms of topic selection, as long it fit to the curriculum.

Updated June 2023

Dr. Christophe Bardin, ESOP Vice President Education

Assist. Mina Kovačevič, Mpharm, spec., Chair of Education in Action